Coiled-coil domain-containing glutamate-rich protein 2 (CCER2)

Coiled-coil domain-containing glutamate-rich protein 2 (CCER2) is a protein primarily expressed in the brain[3][6]. Although its function remains poorly characterized, CCER2 is a secretory protein thought to reside in the extracellular region, and research has identified rare mutations that may contribute to susceptibility to Moyamoya disease—a rare, progressive cerebrovascular disorder[1][3][6]. Despite its name, UniProt notes that predicted coiled-coil regions are likely artifactual and arise from the glutamate-rich sequence rather than true coiled-coil domains[8]. At present, CCER2 is not classified as a therapeutic target such as a receptor, enzyme, or transporter, and no interacting drugs, mechanism of action, or specific safety concerns are established[3][6][8]. The gene's function and role in physiology or pathology remain not well understood[1][6][8]. There is some ambiguity or potential misclassification due to the misleading naming (labeled as "coiled-coil" but lacking a true coiled-coil domain)[8]. Listed as a "potential biomarker," particularly in brain diseases such as Moyamoya, but there is insufficient evidence to treat it as an established disease target or therapeutic receptor[1][3].

Other names

coiled-coil glutamate rich protein 2Gm6537 (mouse)CCER2